市場調査レポート

商品コード

1472192

プレガバリン市場：タイプ別、用途別、流通チャネル別：世界の機会分析と産業予測、2023年～2032年

Pregabalin Market By Type, By Application, By Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2023-2032

出版日: 2024年02月01日
発行: Allied Market Research
ページ情報: 英文 289 Pages
納期: 2～3営業日

価格

PDF (Business License)

USD 5,730 842,252円

レポートPDFを1名がご利用いただけるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。印刷は5回まで可能です。 2名以上でご利用の場合、追加料金を支払う事によりユーザーを最大５名まで追加する事が可能です。

PDF (Enterprise User License) & Excel (Data Pack) & Free Update

USD 9,600 1,411,104円

レポートPDFとExcel定量データをひとつの企業、及びその子会社でご利用頂けるライセンスです。ライセンスを付与されたPCでのみレポートPDFとExcelの保存、表示、利用が可能です。PDFとExcel内のテキスト等のコピー＆ペーストは可能です。PDFとExcelの印刷回数の制限はありません。印刷したレポートの利用は企業、及びその子会社内にて共有可能です。無料でレポートのアップデートがご利用いただけます。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=146.99円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

プレガバリン市場は2022年に16億米ドルと評価され、2023年から2032年までのCAGRは3%を示し、2032年には22億米ドルに達すると推定されます。

プレガバリンは、抗けいれん薬または抗てんかん薬として知られる薬剤群に属します。てんかん、不安障害、神経障害性疼痛が、プレガバリンが主に治療する疾患です。プレガバリンは、ガバペンチノイドとして知られる薬物群のひとつで、特定の神経伝達物質の活性を調節することによって脳内で機能します。

プレガバリンは最初に抗てんかん薬として開発され、その後、線維筋痛症、糖尿病性神経障害、帯状疱疹後神経痛（帯状疱疹後の神経の痛み）など、多くの神経障害性疼痛の治療に有用であることが発見されました。中枢神経系の電位依存性カルシウムチャネルのα2-δサブユニットに結合することにより、サブスタンスP、ノルアドレナリン、グルタミン酸などの神経伝達物質の放出を抑えます。この神経伝達物質の放出の制御により、痛みが起こりにくくなり、脳内の異常な電気活動が安定します。プレガバリンは抗てんかん薬として全般性不安障害（GAD）の治療に用いられます。不安経路に関与するグルタミン酸やノルエピネフリンなどの神経伝達物質の放出を抑制することで、抗不安作用を発揮すると考えられています。

市場を牽引する主な要因は、神経因性疼痛の有病率の急増です。老年人口の増加、糖尿病の罹患率の増加、診断学の進歩はすべて、糖尿病性神経障害や帯状疱疹後神経痛などの神経障害性疼痛疾患の有病率の急増に寄与しています。プレガバリンは、患者数が増加している神経障害性疼痛の治療に有効であることから需要が高く、市場の成長を牽引しています。

てんかんは、繰り返し発作を起こす神経疾患です。さらに、てんかんの発症率は急増しています。ヘルスケアへのアクセスが向上し、この病気に対する認識が高まった結果、てんかんの診断と治療を受ける人が増えています。てんかん患者には発作を抑えるために抗てんかん薬であるプレガバリンが投与され、これが薬剤の需要を高め、市場を牽引しています。

さらに、不安に悩む人の増加がプレガバリンの消費を促進しています。GADの管理薬として承認されたことで、プレガバリンの市場ポテンシャルは、疼痛やてんかんの治療以外にも拡大しています。不安治療におけるプレガバリンの有効性と、メンタルヘルス問題に対する社会的意識の高まりが、この薬剤の市場拡大を後押しする要因となっています。

さらに、末梢性浮腫、体重増加、眠気、めまいなどがプレガバリンの副作用として挙げられます。この薬剤の広範な使用は、誤用、依存、離脱症状の可能性に関する安全性の懸念から制限されています。さらに、プレガバリンは市場において、非薬物療法、理学療法、他の医薬品など、神経障害性疼痛、てんかん、不安障害の代替治療との競合に直面しています。しかし、患者人口の増加、可処分予算の増加、ヘルスケアへのアクセスの改善により、新興市場はプレガバリンメーカーに未開拓の展望を提供しています。価格戦略の変更、流通チャネルの拡大、マーケティングイニシアティブなどの要因が市場成長を促進すると予想されます。

プレガバリン市場は、タイプ、用途、流通チャネル、地域に区分されます。タイプ別では、市場は錠剤・カプセル剤とその他に二分されます。用途別では、神経障害性疼痛、てんかん、その他に分類されます。流通チャネル別では、病院薬局、ドラッグストア・小売薬局、オンラインプロバイダーに分類されます。

地域別では、北米（米国、カナダ、メキシコ）、欧州（ドイツ、フランス、英国、イタリア、スペイン、その他欧州地域）、アジア太平洋（インド、中国、日本、オーストラリア、韓国、その他アジア太平洋地域）、中近東・アフリカ（ブラジル、アルゼンチン、コロンビア、その他アジア太平洋地域）、中東・アフリカ（GCC、南アフリカ、アフリカ、その他アジア太平洋地域）に分析されます。

利害関係者にとっての主なメリット

当レポートは、2022年から2032年までのプレガバリン市場分析の市場セグメント、現在の動向、推定・力学の定量分析を提供し、プレガバリン市場の有力な機会を特定します。

市場促進要因、市場抑制要因、市場機会に関連する情報とともに市場調査を提供します。

ポーターのファイブフォース分析では、利害関係者が利益重視のビジネス決定を下し、サプライヤーとバイヤーのネットワークを強化できるように、バイヤーとサプライヤーの潜在力を強調します。

プレガバリン市場のセグメンテーションを詳細に分析することで、市場機会を見極めることができます。

各地域の主要国は、世界市場への収益貢献度に応じてマッピングされています。

市場プレイヤーのポジショニングは、ベンチマーキングを容易にし、市場プレイヤーの現在のポジションの明確な理解を提供します。

本レポートには、地域別および世界のプレガバリン市場動向、主要企業、市場セグメント、応用分野、市場成長戦略の分析が含まれています。

本レポートで可能なレポートカスタマイズ（追加費用とスケジュールがあります。）

国、地域、世界レベルでの患者/疫学データ
規制ガイドライン
クライアントの関心に応じた追加企業プロファイル
国別または地域別の追加分析-市場規模と予測
企業プロファイルの拡張リスト
過去の市場データ
SWOT分析

概要
北米
- 米国
- カナダ
- メキシコ
欧州
- ドイツ
- フランス
- 英国
- イタリア
- スペイン
- その他
アジア太平洋
- 日本
- 中国
- インド
- オーストラリア
- 韓国
- その他
ラテンアメリカ
- ブラジル
- コロンビア
- アルゼンチン
- その他のラテンアメリカ
中東・アフリカ
- Gcc
- 南アフリカ
- 北アフリカ
- その他の中東・アフリカ

第8章競争情勢

イントロダクション
主要成功戦略
主要10社の製品マッピング
競合ダッシュボード
競合ヒートマップ
主要企業のポジショニング、2022年

第9章企業プロファイル

Viatris Inc.
Rising Pharmaceuticals
Cipla
Lupin Pharmaceuticals
Teva Pharmaceutical Industries Ltd
Markans Pharma Ltd.
Sciegen Pharmaceuticals Inc.
Zydus Group
Novartis AG
Amneal Pharmaceuticals LLC

図表

LIST OF TABLES

TABLE 01. GLOBAL PREGABALIN MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 02. PREGABALIN MARKET FOR TABLETS AND CAPSULES, BY REGION, 2022-2032 ($MILLION)
TABLE 03. PREGABALIN MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
TABLE 04. GLOBAL PREGABALIN MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 05. PREGABALIN MARKET FOR EPILEPSY, BY REGION, 2022-2032 ($MILLION)
TABLE 06. PREGABALIN MARKET FOR NEUROPATHIC PAIN, BY REGION, 2022-2032 ($MILLION)
TABLE 07. PREGABALIN MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
TABLE 08. GLOBAL PREGABALIN MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 09. PREGABALIN MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2022-2032 ($MILLION)
TABLE 10. PREGABALIN MARKET FOR DRUG STORE AND RETAIL PHARMACIES, BY REGION, 2022-2032 ($MILLION)
TABLE 11. PREGABALIN MARKET FOR ONLINE PROVIDERS, BY REGION, 2022-2032 ($MILLION)
TABLE 12. PREGABALIN MARKET, BY REGION, 2022-2032 ($MILLION)
TABLE 13. NORTH AMERICA PREGABALIN MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 14. NORTH AMERICA PREGABALIN MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 15. NORTH AMERICA PREGABALIN MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 16. NORTH AMERICA PREGABALIN MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 17. U.S. PREGABALIN MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 18. U.S. PREGABALIN MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 19. U.S. PREGABALIN MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 20. CANADA PREGABALIN MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 21. CANADA PREGABALIN MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 22. CANADA PREGABALIN MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 23. MEXICO PREGABALIN MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 24. MEXICO PREGABALIN MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 25. MEXICO PREGABALIN MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 26. EUROPE PREGABALIN MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 27. EUROPE PREGABALIN MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 28. EUROPE PREGABALIN MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 29. EUROPE PREGABALIN MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 30. GERMANY PREGABALIN MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 31. GERMANY PREGABALIN MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 32. GERMANY PREGABALIN MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 33. FRANCE PREGABALIN MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 34. FRANCE PREGABALIN MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 35. FRANCE PREGABALIN MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 36. UK PREGABALIN MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 37. UK PREGABALIN MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 38. UK PREGABALIN MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 39. ITALY PREGABALIN MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 40. ITALY PREGABALIN MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 41. ITALY PREGABALIN MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 42. SPAIN PREGABALIN MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 43. SPAIN PREGABALIN MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 44. SPAIN PREGABALIN MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 45. REST OF EUROPE PREGABALIN MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 46. REST OF EUROPE PREGABALIN MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 47. REST OF EUROPE PREGABALIN MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 48. ASIA-PACIFIC PREGABALIN MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 49. ASIA-PACIFIC PREGABALIN MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 50. ASIA-PACIFIC PREGABALIN MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 51. ASIA-PACIFIC PREGABALIN MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 52. JAPAN PREGABALIN MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 53. JAPAN PREGABALIN MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 54. JAPAN PREGABALIN MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 55. CHINA PREGABALIN MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 56. CHINA PREGABALIN MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 57. CHINA PREGABALIN MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 58. INDIA PREGABALIN MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 59. INDIA PREGABALIN MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 60. INDIA PREGABALIN MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 61. AUSTRALIA PREGABALIN MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 62. AUSTRALIA PREGABALIN MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 63. AUSTRALIA PREGABALIN MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 64. SOUTH KOREA PREGABALIN MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 65. SOUTH KOREA PREGABALIN MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 66. SOUTH KOREA PREGABALIN MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 67. REST OF ASIA-PACIFIC PREGABALIN MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 68. REST OF ASIA-PACIFIC PREGABALIN MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 69. REST OF ASIA-PACIFIC PREGABALIN MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 70. LATIN AMERICA PREGABALIN MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 71. LATIN AMERICA PREGABALIN MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 72. LATIN AMERICA PREGABALIN MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 73. LATIN AMERICA PREGABALIN MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 74. BRAZIL PREGABALIN MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 75. BRAZIL PREGABALIN MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 76. BRAZIL PREGABALIN MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 77. COLOMBIA PREGABALIN MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 78. COLOMBIA PREGABALIN MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 79. COLOMBIA PREGABALIN MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 80. ARGENTINA PREGABALIN MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 81. ARGENTINA PREGABALIN MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 82. ARGENTINA PREGABALIN MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 83. REST OF LATIN AMERICA PREGABALIN MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 84. REST OF LATIN AMERICA PREGABALIN MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 85. REST OF LATIN AMERICA PREGABALIN MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 86. MIDDLE EAST AND AFRICA PREGABALIN MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 87. MIDDLE EAST AND AFRICA PREGABALIN MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 88. MIDDLE EAST AND AFRICA PREGABALIN MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 89. MIDDLE EAST AND AFRICA PREGABALIN MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 90. GCC PREGABALIN MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 91. GCC PREGABALIN MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 92. GCC PREGABALIN MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 93. SOUTH AFRICA PREGABALIN MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 94. SOUTH AFRICA PREGABALIN MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 95. SOUTH AFRICA PREGABALIN MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 96. NORTH AFRICA PREGABALIN MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 97. NORTH AFRICA PREGABALIN MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 98. NORTH AFRICA PREGABALIN MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 99. REST OF MIDDLE EAST AND AFRICA PREGABALIN MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 100. REST OF MIDDLE EAST AND AFRICA PREGABALIN MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 101. REST OF MIDDLE EAST AND AFRICA PREGABALIN MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 102. VIATRIS INC.: KEY EXECUTIVES
TABLE 103. VIATRIS INC.: COMPANY SNAPSHOT
TABLE 104. VIATRIS INC.: PRODUCT SEGMENTS
TABLE 105. VIATRIS INC.: SERVICE SEGMENTS
TABLE 106. VIATRIS INC.: PRODUCT PORTFOLIO
TABLE 107. VIATRIS INC.: KEY STRATERGIES
TABLE 108. RISING PHARMACEUTICALS: KEY EXECUTIVES
TABLE 109. RISING PHARMACEUTICALS: COMPANY SNAPSHOT
TABLE 110. RISING PHARMACEUTICALS: PRODUCT SEGMENTS
TABLE 111. RISING PHARMACEUTICALS: SERVICE SEGMENTS
TABLE 112. RISING PHARMACEUTICALS: PRODUCT PORTFOLIO
TABLE 113. RISING PHARMACEUTICALS: KEY STRATERGIES
TABLE 114. CIPLA: KEY EXECUTIVES
TABLE 115. CIPLA: COMPANY SNAPSHOT
TABLE 116. CIPLA: PRODUCT SEGMENTS
TABLE 117. CIPLA: SERVICE SEGMENTS
TABLE 118. CIPLA: PRODUCT PORTFOLIO
TABLE 119. CIPLA: KEY STRATERGIES
TABLE 120. LUPIN PHARMACEUTICALS: KEY EXECUTIVES
TABLE 121. LUPIN PHARMACEUTICALS: COMPANY SNAPSHOT
TABLE 122. LUPIN PHARMACEUTICALS: PRODUCT SEGMENTS
TABLE 123. LUPIN PHARMACEUTICALS: SERVICE SEGMENTS
TABLE 124. LUPIN PHARMACEUTICALS: PRODUCT PORTFOLIO
TABLE 125. LUPIN PHARMACEUTICALS: KEY STRATERGIES
TABLE 126. TEVA PHARMACEUTICAL INDUSTRIES LTD: KEY EXECUTIVES
TABLE 127. TEVA PHARMACEUTICAL INDUSTRIES LTD: COMPANY SNAPSHOT
TABLE 128. TEVA PHARMACEUTICAL INDUSTRIES LTD: PRODUCT SEGMENTS
TABLE 129. TEVA PHARMACEUTICAL INDUSTRIES LTD: SERVICE SEGMENTS
TABLE 130. TEVA PHARMACEUTICAL INDUSTRIES LTD: PRODUCT PORTFOLIO
TABLE 131. TEVA PHARMACEUTICAL INDUSTRIES LTD: KEY STRATERGIES
TABLE 132. MARKANS PHARMA LTD.: KEY EXECUTIVES
TABLE 133. MARKANS PHARMA LTD.: COMPANY SNAPSHOT
TABLE 134. MARKANS PHARMA LTD.: PRODUCT SEGMENTS
TABLE 135. MARKANS PHARMA LTD.: SERVICE SEGMENTS
TABLE 136. MARKANS PHARMA LTD.: PRODUCT PORTFOLIO
TABLE 137. MARKANS PHARMA LTD.: KEY STRATERGIES
TABLE 138. SCIEGEN PHARMACEUTICALS INC.: KEY EXECUTIVES
TABLE 139. SCIEGEN PHARMACEUTICALS INC.: COMPANY SNAPSHOT
TABLE 140. SCIEGEN PHARMACEUTICALS INC.: PRODUCT SEGMENTS
TABLE 141. SCIEGEN PHARMACEUTICALS INC.: SERVICE SEGMENTS
TABLE 142. SCIEGEN PHARMACEUTICALS INC.: PRODUCT PORTFOLIO
TABLE 143. SCIEGEN PHARMACEUTICALS INC.: KEY STRATERGIES
TABLE 144. ZYDUS GROUP: KEY EXECUTIVES
TABLE 145. ZYDUS GROUP: COMPANY SNAPSHOT
TABLE 146. ZYDUS GROUP: PRODUCT SEGMENTS
TABLE 147. ZYDUS GROUP: SERVICE SEGMENTS
TABLE 148. ZYDUS GROUP: PRODUCT PORTFOLIO
TABLE 149. ZYDUS GROUP: KEY STRATERGIES
TABLE 150. NOVARTIS AG: KEY EXECUTIVES
TABLE 151. NOVARTIS AG: COMPANY SNAPSHOT
TABLE 152. NOVARTIS AG: PRODUCT SEGMENTS
TABLE 153. NOVARTIS AG: SERVICE SEGMENTS
TABLE 154. NOVARTIS AG: PRODUCT PORTFOLIO
TABLE 155. NOVARTIS AG: KEY STRATERGIES
TABLE 156. AMNEAL PHARMACEUTICALS LLC: KEY EXECUTIVES
TABLE 157. AMNEAL PHARMACEUTICALS LLC: COMPANY SNAPSHOT
TABLE 158. AMNEAL PHARMACEUTICALS LLC: PRODUCT SEGMENTS
TABLE 159. AMNEAL PHARMACEUTICALS LLC: SERVICE SEGMENTS
TABLE 160. AMNEAL PHARMACEUTICALS LLC: PRODUCT PORTFOLIO
TABLE 161. AMNEAL PHARMACEUTICALS LLC: KEY STRATERGIES

LIST OF FIGURES

FIGURE 01. PREGABALIN MARKET, 2022-2032
FIGURE 02. SEGMENTATION OF PREGABALIN MARKET,2022-2032
FIGURE 03. TOP IMPACTING FACTORS IN PREGABALIN MARKET
FIGURE 04. TOP INVESTMENT POCKETS IN PREGABALIN MARKET (2023-2032)
FIGURE 05. BARGAINING POWER OF SUPPLIERS
FIGURE 06. BARGAINING POWER OF BUYERS
FIGURE 07. THREAT OF SUBSTITUTION
FIGURE 08. THREAT OF SUBSTITUTION
FIGURE 09. COMPETITIVE RIVALRY
FIGURE 10. GLOBAL PREGABALIN MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
FIGURE 11. PREGABALIN MARKET, BY TYPE, 2022 AND 2032(%)
FIGURE 12. COMPARATIVE SHARE ANALYSIS OF PREGABALIN MARKET FOR TABLETS AND CAPSULES, BY COUNTRY 2022 AND 2032(%)
FIGURE 13. COMPARATIVE SHARE ANALYSIS OF PREGABALIN MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
FIGURE 14. PREGABALIN MARKET, BY APPLICATION, 2022 AND 2032(%)
FIGURE 15. COMPARATIVE SHARE ANALYSIS OF PREGABALIN MARKET FOR EPILEPSY, BY COUNTRY 2022 AND 2032(%)
FIGURE 16. COMPARATIVE SHARE ANALYSIS OF PREGABALIN MARKET FOR NEUROPATHIC PAIN, BY COUNTRY 2022 AND 2032(%)
FIGURE 17. COMPARATIVE SHARE ANALYSIS OF PREGABALIN MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
FIGURE 18. PREGABALIN MARKET, BY DISTRIBUTION CHANNEL, 2022 AND 2032(%)
FIGURE 19. COMPARATIVE SHARE ANALYSIS OF PREGABALIN MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY 2022 AND 2032(%)
FIGURE 20. COMPARATIVE SHARE ANALYSIS OF PREGABALIN MARKET FOR DRUG STORE AND RETAIL PHARMACIES, BY COUNTRY 2022 AND 2032(%)
FIGURE 21. COMPARATIVE SHARE ANALYSIS OF PREGABALIN MARKET FOR ONLINE PROVIDERS, BY COUNTRY 2022 AND 2032(%)
FIGURE 22. PREGABALIN MARKET BY REGION, 2022 AND 2032(%)
FIGURE 23. U.S. PREGABALIN MARKET, 2022-2032 ($MILLION)
FIGURE 24. CANADA PREGABALIN MARKET, 2022-2032 ($MILLION)
FIGURE 25. MEXICO PREGABALIN MARKET, 2022-2032 ($MILLION)
FIGURE 26. GERMANY PREGABALIN MARKET, 2022-2032 ($MILLION)
FIGURE 27. FRANCE PREGABALIN MARKET, 2022-2032 ($MILLION)
FIGURE 28. UK PREGABALIN MARKET, 2022-2032 ($MILLION)
FIGURE 29. ITALY PREGABALIN MARKET, 2022-2032 ($MILLION)
FIGURE 30. SPAIN PREGABALIN MARKET, 2022-2032 ($MILLION)
FIGURE 31. REST OF EUROPE PREGABALIN MARKET, 2022-2032 ($MILLION)
FIGURE 32. JAPAN PREGABALIN MARKET, 2022-2032 ($MILLION)
FIGURE 33. CHINA PREGABALIN MARKET, 2022-2032 ($MILLION)
FIGURE 34. INDIA PREGABALIN MARKET, 2022-2032 ($MILLION)
FIGURE 35. AUSTRALIA PREGABALIN MARKET, 2022-2032 ($MILLION)
FIGURE 36. SOUTH KOREA PREGABALIN MARKET, 2022-2032 ($MILLION)
FIGURE 37. REST OF ASIA-PACIFIC PREGABALIN MARKET, 2022-2032 ($MILLION)
FIGURE 38. BRAZIL PREGABALIN MARKET, 2022-2032 ($MILLION)
FIGURE 39. COLOMBIA PREGABALIN MARKET, 2022-2032 ($MILLION)
FIGURE 40. ARGENTINA PREGABALIN MARKET, 2022-2032 ($MILLION)
FIGURE 41. REST OF LATIN AMERICA PREGABALIN MARKET, 2022-2032 ($MILLION)
FIGURE 42. GCC PREGABALIN MARKET, 2022-2032 ($MILLION)
FIGURE 43. SOUTH AFRICA PREGABALIN MARKET, 2022-2032 ($MILLION)
FIGURE 44. NORTH AFRICA PREGABALIN MARKET, 2022-2032 ($MILLION)
FIGURE 45. REST OF MIDDLE EAST AND AFRICA PREGABALIN MARKET, 2022-2032 ($MILLION)
FIGURE 46. TOP WINNING STRATEGIES, BY YEAR
FIGURE 47. TOP WINNING STRATEGIES, BY DEVELOPMENT
FIGURE 48. TOP WINNING STRATEGIES, BY COMPANY
FIGURE 49. PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 50. COMPETITIVE DASHBOARD
FIGURE 51. COMPETITIVE HEATMAP: PREGABALIN MARKET
FIGURE 52. TOP PLAYER POSITIONING, 2022

Product Code: A02320

The pregabalin market was valued at $1.6 billion in 2022 and is estimated to reach $2.2 billion by 2032, exhibiting a CAGR of 3% from 2023 to 2032. Pregabalin belongs to a group of drugs known as anticonvulsants or antiepileptic drugs. Epilepsy, anxiety disorder, and neuropathic pain are the main conditions that pregabalin treats majorly. It is a member of the class of medications known as gabapentinoids, which function in the brain by modifying the activity of specific neurotransmitters.

Pregabalin was first developed as an antiepileptic medication, then it was subsequently discovered to be useful in treating a number of neuropathic pain conditions, such as fibromyalgia, diabetic neuropathy, and postherpetic neuralgia (pain in the nerves after shingles). By binding to the alpha-2-delta subunit of voltage-gated calcium channels in the central nervous system, it reduces the release of neurotransmitters such as substance P, noradrenaline, and glutamate. This control over the release of neurotransmitters lessens the likelihood of pain and stabilizes aberrant electrical activity in the brain. Pregabalin is used as an antiepileptic drug to treat generalized anxiety disorder (GAD). It is believed to have an anxiolytic effect by inhibiting the release of neurotransmitters, including glutamate and norepinephrine that are involved in anxiety pathways.

The major factor that drives the market is the surge in prevalence of neuropathic pain. Rise in geriatric population, an increase in the incidence of diabetes, and advancements in diagnostics have all contributed to a surge in the prevalence of neuropathic pain diseases, such as diabetic neuropathy and postherpetic neuralgia. Pregabalin is in high demand due to its efficacy in treating neuropathic pain, which is experienced by an increasing number of patients, thereby driving the growth of the market.

Epilepsy is a neurological illness marked by recurring seizures. Moreover, there is a surge in the incidence of epilepsy. More people receive epilepsy diagnoses and treatments as a result of greater healthcare accessibility and rise in awareness of the ailment. Patients with epilepsy are provided pregabalin, an antiepileptic treatment, to control their seizures, which increases demand for the drug, thus driving the market.

Furthermore, the rise in the number of individuals suffering from the anxiety fosters the consumption of pregabalin. With its approval for the management of GAD, the market potential of pregabalin has grown beyond the treatment of pain and epilepsy. The effectiveness of pregabalin in treating anxiety and the rise in public awareness of mental health issues are factors that drive the market expansion of this drug.

Moreover, peripheral edema, weight gain, sleepiness, and dizziness are among the side effects of pregabalin. The broad use of this medication is restricted due to safety concerns, namely pertaining to the possibility of misuse, dependence, and withdrawal symptoms. Moreover, pregabalin faces competition in the market from alternative treatments for neuropathic pain, epilepsy, and anxiety disorders, such as non-pharmacological therapies, physical therapy, and other pharmaceuticals. However, due to rise in patient population, increased disposable budgets, and improved access to healthcare, emerging markets offer pregabalin manufacturers unexplored prospects. Factors such as modifying price strategies, expanding distribution channels, and marketing initiatives are anticipated to drive market growth.

The pregabalin market is segmented into type, application, distribution channel, and region. On the basis of type, the market is bifurcated into tablet & capsules and others. On the basis of application, the market is classified into neuropathic pain, epilepsy, and others. On the basis of distribution channel, the market is categorized into hospital pharmacies, drug store & retail pharmacies, and online providers.

On the basis of region, market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and the rest of Europe), Asia-Pacific (India, China, Japan, Australia, South Korea, and rest of Asia-Pacific), and Latin America (Brazil, Argentina, Colombia, and rest of Latin America), and Middle East & Africa (GCC, South Africa, North Africa, and rest of LAMEA).

The major players that operate in the pregabalin market include Viatris Inc., Cipla, Amneal Pharmaceuticals, Rising Pharmaceutical, Teva Pharmaceutical, Lupin, ScieGen Pharmaceuticals Inc., Zydus, Medley Pharmaceuticals Ltd., and Novartis AG. The key players have adopted key strategies such as product launch to expand their product portfolio.

Key Benefits for Stakeholders

This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the pregabalin market analysis from 2022 to 2032 to identify the prevailing pregabalin market opportunities.

The market research is offered along with information related to key drivers, restraints, and opportunities.

Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.

In-depth analysis of the pregabalin market segmentation assists to determine the prevailing market opportunities.

Major countries in each region are mapped according to their revenue contribution to the global market.

Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.

The report includes the analysis of the regional as well as global pregabalin market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

Quarterly Update and* (only available with a corporate license, on listed price)
5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
Free Upcoming Version on the Purchase of Five and Enterprise User License.
16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
Free data Pack on the Five and Enterprise User License. (Excel version of the report)
Free Updated report if the report is 6-12 months old or older.
24-hour priority response*
Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

Patient/epidemiology data at country, region, global level
Regulatory Guidelines
Additional company profiles with specific to client's interest
Additional country or region analysis- market size and forecast
Expanded list for Company Profiles
Historic market data
SWOT Analysis

Key Market Segments

By Type

Tablets and Capsules
Others

By Application

Epilepsy
Neuropathic Pain
Others

By Distribution Channel

Hospital Pharmacies
Drug Store and Retail Pharmacies
Online Providers

By Region

North America
- U.S.
- Canada
- Mexico
Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Colombia
- Argentina
- Rest of Latin America
Middle East and Africa
- Gcc
- South Africa
- North Africa
- Rest of Middle East And Africa

Key Market Players:

Viatris Inc.
Rising Pharmaceuticals
Cipla
Lupin Pharmaceuticals
Teva Pharmaceutical Industries Ltd
Markans Pharma Ltd.
Sciegen Pharmaceuticals Inc.
Zydus Group
Novartis AG
Amneal Pharmaceuticals LLC

CHAPTER 1: INTRODUCTION

1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research methodology
- 1.4.1. Primary research
- 1.4.2. Secondary research
- 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. CXO perspective

CHAPTER 3: MARKET OVERVIEW

3.1. Market definition and scope
3.2. Key findings
- 3.2.1. Top impacting factors
- 3.2.2. Top investment pockets
3.3. Porter's five forces analysis
3.4. Market dynamics
- 3.4.1. Drivers
- 3.4.2. Restraints
- 3.4.3. Opportunities

CHAPTER 4: PREGABALIN MARKET, BY TYPE

4.1. Overview
- 4.1.1. Market size and forecast
4.2. Tablets and Capsules
- 4.2.1. Key market trends, growth factors and opportunities
- 4.2.2. Market size and forecast, by region
- 4.2.3. Market share analysis by country
4.3. Others
- 4.3.1. Key market trends, growth factors and opportunities
- 4.3.2. Market size and forecast, by region
- 4.3.3. Market share analysis by country

CHAPTER 5: PREGABALIN MARKET, BY APPLICATION

5.1. Overview
- 5.1.1. Market size and forecast
5.2. Epilepsy
- 5.2.1. Key market trends, growth factors and opportunities
- 5.2.2. Market size and forecast, by region
- 5.2.3. Market share analysis by country
5.3. Neuropathic Pain
- 5.3.1. Key market trends, growth factors and opportunities
- 5.3.2. Market size and forecast, by region
- 5.3.3. Market share analysis by country
5.4. Others
- 5.4.1. Key market trends, growth factors and opportunities
- 5.4.2. Market size and forecast, by region
- 5.4.3. Market share analysis by country

CHAPTER 6: PREGABALIN MARKET, BY DISTRIBUTION CHANNEL

6.1. Overview
- 6.1.1. Market size and forecast
6.2. Hospital Pharmacies
- 6.2.1. Key market trends, growth factors and opportunities
- 6.2.2. Market size and forecast, by region
- 6.2.3. Market share analysis by country
6.3. Drug Store and Retail Pharmacies
- 6.3.1. Key market trends, growth factors and opportunities
- 6.3.2. Market size and forecast, by region
- 6.3.3. Market share analysis by country
6.4. Online Providers
- 6.4.1. Key market trends, growth factors and opportunities
- 6.4.2. Market size and forecast, by region
- 6.4.3. Market share analysis by country

CHAPTER 7: PREGABALIN MARKET, BY REGION

7.1. Overview
- 7.1.1. Market size and forecast By Region
7.2. North America
- 7.2.1. Key market trends, growth factors and opportunities
- 7.2.2. Market size and forecast, by Type
- 7.2.3. Market size and forecast, by Application
- 7.2.4. Market size and forecast, by Distribution Channel
- 7.2.5. Market size and forecast, by country
  - 7.2.5.1. U.S.
  - 7.2.5.1.1. Market size and forecast, by Type
  - 7.2.5.1.2. Market size and forecast, by Application
  - 7.2.5.1.3. Market size and forecast, by Distribution Channel
  - 7.2.5.2. Canada
  - 7.2.5.2.1. Market size and forecast, by Type
  - 7.2.5.2.2. Market size and forecast, by Application
  - 7.2.5.2.3. Market size and forecast, by Distribution Channel
  - 7.2.5.3. Mexico
  - 7.2.5.3.1. Market size and forecast, by Type
  - 7.2.5.3.2. Market size and forecast, by Application
  - 7.2.5.3.3. Market size and forecast, by Distribution Channel
7.3. Europe
- 7.3.1. Key market trends, growth factors and opportunities
- 7.3.2. Market size and forecast, by Type
- 7.3.3. Market size and forecast, by Application
- 7.3.4. Market size and forecast, by Distribution Channel
- 7.3.5. Market size and forecast, by country
  - 7.3.5.1. Germany
  - 7.3.5.1.1. Market size and forecast, by Type
  - 7.3.5.1.2. Market size and forecast, by Application
  - 7.3.5.1.3. Market size and forecast, by Distribution Channel
  - 7.3.5.2. France
  - 7.3.5.2.1. Market size and forecast, by Type
  - 7.3.5.2.2. Market size and forecast, by Application
  - 7.3.5.2.3. Market size and forecast, by Distribution Channel
  - 7.3.5.3. UK
  - 7.3.5.3.1. Market size and forecast, by Type
  - 7.3.5.3.2. Market size and forecast, by Application
  - 7.3.5.3.3. Market size and forecast, by Distribution Channel
  - 7.3.5.4. Italy
  - 7.3.5.4.1. Market size and forecast, by Type
  - 7.3.5.4.2. Market size and forecast, by Application
  - 7.3.5.4.3. Market size and forecast, by Distribution Channel
  - 7.3.5.5. Spain
  - 7.3.5.5.1. Market size and forecast, by Type
  - 7.3.5.5.2. Market size and forecast, by Application
  - 7.3.5.5.3. Market size and forecast, by Distribution Channel
  - 7.3.5.6. Rest of Europe
  - 7.3.5.6.1. Market size and forecast, by Type
  - 7.3.5.6.2. Market size and forecast, by Application
  - 7.3.5.6.3. Market size and forecast, by Distribution Channel
7.4. Asia-Pacific
- 7.4.1. Key market trends, growth factors and opportunities
- 7.4.2. Market size and forecast, by Type
- 7.4.3. Market size and forecast, by Application
- 7.4.4. Market size and forecast, by Distribution Channel
- 7.4.5. Market size and forecast, by country
  - 7.4.5.1. Japan
  - 7.4.5.1.1. Market size and forecast, by Type
  - 7.4.5.1.2. Market size and forecast, by Application
  - 7.4.5.1.3. Market size and forecast, by Distribution Channel
  - 7.4.5.2. China
  - 7.4.5.2.1. Market size and forecast, by Type
  - 7.4.5.2.2. Market size and forecast, by Application
  - 7.4.5.2.3. Market size and forecast, by Distribution Channel
  - 7.4.5.3. India
  - 7.4.5.3.1. Market size and forecast, by Type
  - 7.4.5.3.2. Market size and forecast, by Application
  - 7.4.5.3.3. Market size and forecast, by Distribution Channel
  - 7.4.5.4. Australia
  - 7.4.5.4.1. Market size and forecast, by Type
  - 7.4.5.4.2. Market size and forecast, by Application
  - 7.4.5.4.3. Market size and forecast, by Distribution Channel
  - 7.4.5.5. South Korea
  - 7.4.5.5.1. Market size and forecast, by Type
  - 7.4.5.5.2. Market size and forecast, by Application
  - 7.4.5.5.3. Market size and forecast, by Distribution Channel
  - 7.4.5.6. Rest of Asia-Pacific
  - 7.4.5.6.1. Market size and forecast, by Type
  - 7.4.5.6.2. Market size and forecast, by Application
  - 7.4.5.6.3. Market size and forecast, by Distribution Channel
7.5. Latin America
- 7.5.1. Key market trends, growth factors and opportunities
- 7.5.2. Market size and forecast, by Type
- 7.5.3. Market size and forecast, by Application
- 7.5.4. Market size and forecast, by Distribution Channel
- 7.5.5. Market size and forecast, by country
  - 7.5.5.1. Brazil
  - 7.5.5.1.1. Market size and forecast, by Type
  - 7.5.5.1.2. Market size and forecast, by Application
  - 7.5.5.1.3. Market size and forecast, by Distribution Channel
  - 7.5.5.2. Colombia
  - 7.5.5.2.1. Market size and forecast, by Type
  - 7.5.5.2.2. Market size and forecast, by Application
  - 7.5.5.2.3. Market size and forecast, by Distribution Channel
  - 7.5.5.3. Argentina
  - 7.5.5.3.1. Market size and forecast, by Type
  - 7.5.5.3.2. Market size and forecast, by Application
  - 7.5.5.3.3. Market size and forecast, by Distribution Channel
  - 7.5.5.4. Rest of Latin America
  - 7.5.5.4.1. Market size and forecast, by Type
  - 7.5.5.4.2. Market size and forecast, by Application
  - 7.5.5.4.3. Market size and forecast, by Distribution Channel
7.6. Middle East and Africa
- 7.6.1. Key market trends, growth factors and opportunities
- 7.6.2. Market size and forecast, by Type
- 7.6.3. Market size and forecast, by Application
- 7.6.4. Market size and forecast, by Distribution Channel
- 7.6.5. Market size and forecast, by country
  - 7.6.5.1. Gcc
  - 7.6.5.1.1. Market size and forecast, by Type
  - 7.6.5.1.2. Market size and forecast, by Application
  - 7.6.5.1.3. Market size and forecast, by Distribution Channel
  - 7.6.5.2. South Africa
  - 7.6.5.2.1. Market size and forecast, by Type
  - 7.6.5.2.2. Market size and forecast, by Application
  - 7.6.5.2.3. Market size and forecast, by Distribution Channel
  - 7.6.5.3. North Africa
  - 7.6.5.3.1. Market size and forecast, by Type
  - 7.6.5.3.2. Market size and forecast, by Application
  - 7.6.5.3.3. Market size and forecast, by Distribution Channel
  - 7.6.5.4. Rest of Middle East And Africa
  - 7.6.5.4.1. Market size and forecast, by Type
  - 7.6.5.4.2. Market size and forecast, by Application
  - 7.6.5.4.3. Market size and forecast, by Distribution Channel

CHAPTER 8: COMPETITIVE LANDSCAPE

8.1. Introduction
8.2. Top winning strategies
8.3. Product mapping of top 10 player
8.4. Competitive dashboard
8.5. Competitive heatmap
8.6. Top player positioning, 2022

CHAPTER 9: COMPANY PROFILES

9.1. Viatris Inc.
- 9.1.1. Company overview
- 9.1.2. Key executives
- 9.1.3. Company snapshot
- 9.1.4. Operating business segments
- 9.1.5. Product portfolio
- 9.1.6. Business performance
- 9.1.7. Key strategic moves and developments
9.2. Rising Pharmaceuticals
- 9.2.1. Company overview
- 9.2.2. Key executives
- 9.2.3. Company snapshot
- 9.2.4. Operating business segments
- 9.2.5. Product portfolio
- 9.2.6. Business performance
- 9.2.7. Key strategic moves and developments
9.3. Cipla
- 9.3.1. Company overview
- 9.3.2. Key executives
- 9.3.3. Company snapshot
- 9.3.4. Operating business segments
- 9.3.5. Product portfolio
- 9.3.6. Business performance
- 9.3.7. Key strategic moves and developments
9.4. Lupin Pharmaceuticals
- 9.4.1. Company overview
- 9.4.2. Key executives
- 9.4.3. Company snapshot
- 9.4.4. Operating business segments
- 9.4.5. Product portfolio
- 9.4.6. Business performance
- 9.4.7. Key strategic moves and developments
9.5. Teva Pharmaceutical Industries Ltd
- 9.5.1. Company overview
- 9.5.2. Key executives
- 9.5.3. Company snapshot
- 9.5.4. Operating business segments
- 9.5.5. Product portfolio
- 9.5.6. Business performance
- 9.5.7. Key strategic moves and developments
9.6. Markans Pharma Ltd.
- 9.6.1. Company overview
- 9.6.2. Key executives
- 9.6.3. Company snapshot
- 9.6.4. Operating business segments
- 9.6.5. Product portfolio
- 9.6.6. Business performance
- 9.6.7. Key strategic moves and developments
9.7. Sciegen Pharmaceuticals Inc.
- 9.7.1. Company overview
- 9.7.2. Key executives
- 9.7.3. Company snapshot
- 9.7.4. Operating business segments
- 9.7.5. Product portfolio
- 9.7.6. Business performance
- 9.7.7. Key strategic moves and developments
9.8. Zydus Group
- 9.8.1. Company overview
- 9.8.2. Key executives
- 9.8.3. Company snapshot
- 9.8.4. Operating business segments
- 9.8.5. Product portfolio
- 9.8.6. Business performance
- 9.8.7. Key strategic moves and developments
9.9. Novartis AG
- 9.9.1. Company overview
- 9.9.2. Key executives
- 9.9.3. Company snapshot
- 9.9.4. Operating business segments
- 9.9.5. Product portfolio
- 9.9.6. Business performance
- 9.9.7. Key strategic moves and developments
9.10. Amneal Pharmaceuticals LLC
- 9.10.1. Company overview
- 9.10.2. Key executives
- 9.10.3. Company snapshot
- 9.10.4. Operating business segments
- 9.10.5. Product portfolio
- 9.10.6. Business performance
- 9.10.7. Key strategic moves and developments

プレガバリン市場：タイプ別、用途別、流通チャネル別：世界の機会分析と産業予測、2023年～2032年

Pregabalin Market By Type, By Application, By Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2023-2032

目次

第1章イントロダクション

第2章エグゼクティブサマリー

第3章市場概要

第4章プレガバリン市場：タイプ別

第5章プレガバリン市場：用途別

第6章プレガバリン市場：流通チャネル別

第7章プレガバリン市場：地域別

第8章競争情勢

第9章企業プロファイル

LIST OF TABLES

LIST OF FIGURES

Key Market Segments

By Type

By Application

By Distribution Channel

By Region

Key Market Players:

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

CHAPTER 2: EXECUTIVE SUMMARY

CHAPTER 3: MARKET OVERVIEW

CHAPTER 4: PREGABALIN MARKET, BY TYPE

CHAPTER 5: PREGABALIN MARKET, BY APPLICATION

CHAPTER 6: PREGABALIN MARKET, BY DISTRIBUTION CHANNEL

CHAPTER 7: PREGABALIN MARKET, BY REGION

CHAPTER 8: COMPETITIVE LANDSCAPE

CHAPTER 9: COMPANY PROFILES

プレガバリン市場：タイプ別、用途別、流通チャネル別：世界の機会分析と産業予測、2023年～2032年

Pregabalin Market By Type, By Application, By Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2023-2032

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 市場概要

第4章 プレガバリン市場：タイプ別

第5章 プレガバリン市場：用途別

第6章 プレガバリン市場：流通チャネル別

第7章 プレガバリン市場：地域別

第8章 競争情勢

第9章 企業プロファイル

LIST OF TABLES

LIST OF FIGURES

Key Market Segments

By Type

By Application

By Distribution Channel

By Region

Key Market Players:

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

CHAPTER 2: EXECUTIVE SUMMARY

CHAPTER 3: MARKET OVERVIEW

CHAPTER 4: PREGABALIN MARKET, BY TYPE

CHAPTER 5: PREGABALIN MARKET, BY APPLICATION

CHAPTER 6: PREGABALIN MARKET, BY DISTRIBUTION CHANNEL

CHAPTER 7: PREGABALIN MARKET, BY REGION

CHAPTER 8: COMPETITIVE LANDSCAPE

CHAPTER 9: COMPANY PROFILES

第1章イントロダクション

第2章エグゼクティブサマリー

第3章市場概要

第4章プレガバリン市場：タイプ別

第5章プレガバリン市場：用途別

第6章プレガバリン市場：流通チャネル別

第7章プレガバリン市場：地域別

第8章競争情勢

第9章企業プロファイル